Prognostic value of admission hyperglycemia on outcomes of thrombolysis in ischemic stroke patients with or without diabetes

Hong-Juan Fang,Yue-Song Pan,Yong-Jun Wang,Chun-Xue Wang,Yi-Long Wang,Li-Yong Zhong
DOI: https://doi.org/10.1097/cm9.0000000000001005
IF: 6.133
2020-09-11
Chinese Medical Journal
Abstract:Thrombolytic therapy within 4.5 h from symptom onset is a recognized effective and standard therapy for acute ischemic stroke (AIS), but some patients still have a poor clinical outcome. The evaluation and control of predictors for AIS poor clinical outcomes is integral to achieving optimal treatments, but the prognostic value of admission blood glucose (ABG) for this purpose is unclear and still under debate. ABG evaluated in patients without diabetes mellitus (DM) often suggests acute stress hyperglycemia, while ABG may have a close relationship with long-term blood glucose control in patients with DM. However, in most studies about the influence of ABG on the prognosis of recombinant tissue-type plasminogen activator (rtPA) therapy after AIS, patients were not classified into those with and without DM. The present study was designed to investigate the prognostic value of ABG for clinical outcomes of AIS after thrombolysis according to DM status in a Chinese population.
medicine, general & internal
What problem does this paper attempt to address?
This paper aims to explore the prognostic value of admission blood glucose (ABG) levels on clinical outcomes in ischemic stroke patients after thrombolytic therapy, with a particular focus on the impact of diabetes mellitus (DM) status on this relationship. Specifically, the study seeks to answer the following questions: 1. **Is admission hyperglycemia associated with adverse clinical outcomes after thrombolytic therapy?** 2. **Is there a difference in this relationship between diabetic and non-diabetic patients?** The background of the study indicates that although thrombolytic therapy is the standard treatment for acute ischemic stroke (AIS), some patients may still experience adverse clinical outcomes. Evaluating and controlling the predictive factors that influence these adverse outcomes is crucial for optimizing treatment. However, the value of admission blood glucose as a predictive factor remains unclear, and in most related studies, diabetic and non-diabetic patients have not been distinguished. Therefore, this study analyzes data from the Thrombolysis Implementation and Monitor of Ischemic Stroke in China (TIMS-China) to investigate the prognostic value of admission blood glucose levels in diabetic and non-diabetic patients. The primary aim of the study is to determine whether admission hyperglycemia independently predicts adverse clinical outcomes in non-diabetic patients and whether a history of diabetes increases the risk of symptomatic intracranial hemorrhage (sICH) after thrombolytic therapy.